X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (748) 748
Publication (40) 40
Book Review (8) 8
Conference Proceeding (6) 6
Book Chapter (5) 5
Book / eBook (3) 3
Newspaper Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (566) 566
index medicus (342) 342
male (288) 288
female (228) 228
coagulants - therapeutic use (215) 215
treatment outcome (194) 194
coagulants - adverse effects (191) 191
middle aged (186) 186
coagulants (184) 184
adult (176) 176
hematology (157) 157
aged (150) 150
coagulants - administration & dosage (138) 138
coagulation (109) 109
peripheral vascular disease (105) 105
anticoagulants - adverse effects (103) 103
surgery (98) 98
animals (93) 93
risk factors (93) 93
blood coagulation - drug effects (90) 90
recombinant proteins - therapeutic use (85) 85
hemophilia a - drug therapy (84) 84
time factors (81) 81
adolescent (76) 76
anticoagulants (76) 76
child (72) 72
thrombosis (70) 70
hemorrhage (67) 67
factor viia - therapeutic use (66) 66
environmental sciences (62) 62
hemophilia (61) 61
retrospective studies (61) 61
hemorrhage - drug therapy (60) 60
young adult (59) 59
aged, 80 and over (58) 58
water treatment (58) 58
warfarin (55) 55
safety (54) 54
cardiac & cardiovascular systems (53) 53
management (52) 52
factor viii - adverse effects (51) 51
therapy (49) 49
water resources (49) 49
factor viii - therapeutic use (48) 48
removal (48) 48
drug administration schedule (47) 47
activated factor-vii (46) 46
care and treatment (46) 46
efficacy (46) 46
hemorrhage - prevention & control (46) 46
recombinant proteins - adverse effects (46) 46
anticoagulants - administration & dosage (45) 45
hemorrhage - chemically induced (45) 45
inhibitors (45) 45
thrombin (44) 44
child, preschool (42) 42
turbidity (42) 42
factor viia - adverse effects (41) 41
risk assessment (41) 41
blood loss, surgical - prevention & control (40) 40
hemorrhage - etiology (40) 40
infant (40) 40
recombinant proteins - administration & dosage (40) 40
bleeding (39) 39
engineering, environmental (39) 39
flocculation (39) 39
hemophilia a - blood (39) 39
hemophilia a - complications (39) 39
prospective studies (38) 38
prothrombin complex concentrate (38) 38
analysis (37) 37
plasma (37) 37
coagulants - pharmacology (36) 36
medicine, general & internal (36) 36
blood (35) 35
dose-response relationship, drug (35) 35
aluminum (34) 34
pharmacokinetics (34) 34
prophylaxis (34) 34
warfarin - adverse effects (34) 34
administration, oral (33) 33
blood coagulation factors - therapeutic use (33) 33
drinking water (33) 33
health aspects (33) 33
risk (33) 33
coagulants - pharmacokinetics (32) 32
patients (32) 32
anticoagulants - therapeutic use (31) 31
coagulants - immunology (31) 31
intracerebral hemorrhage (31) 31
medicine (31) 31
medicine & public health (31) 31
postoperative hemorrhage - etiology (31) 31
proteins (31) 31
anesthesiology (30) 30
blood coagulation factors - adverse effects (30) 30
drugs (30) 30
factor viii - administration & dosage (30) 30
pharmacology & pharmacy (30) 30
severity of illness index (30) 30
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (734) 734
Russian (6) 6
French (4) 4
Chinese (2) 2
Italian (2) 2
Japanese (2) 2
Spanish (2) 2
Danish (1) 1
German (1) 1
Norwegian (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Archives of Cardiovascular Diseases, ISSN 1875-2136, 2013, Volume 106, Issue 6, pp. 382 - 393
Summary Direct new oral anticoagulants (NOACs) – inhibitors of thrombin or factor Xa – are intended to be used largely in the treatment of venous... 
Cardiovascular | Internal Medicine | Réversion | Hémorragie | Surgery | Reversal | Chirurgie | Anti-Xa | Bleeding | Anti-IIa | CARDIAC & CARDIOVASCULAR SYSTEMS | ASSAYS LABORATORY RECOMMENDATIONS | RIVAROXABAN | PHARMACODYNAMICS | COAGULATION ASSAYS | ATRIAL-FIBRILLATION | DABIGATRAN ETEXILATE | PHARMACOKINETICS | WARFARIN | PROTHROMBIN COMPLEX CONCENTRATE | Anti-lla | Perioperative Care | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Postoperative Hemorrhage - diagnosis | Postoperative Hemorrhage - chemically induced | Antithrombins - administration & dosage | Dabigatran | Drug Monitoring - methods | Rivaroxaban | Time Factors | Patient Safety | Benzimidazoles - adverse effects | Postoperative Hemorrhage - therapy | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Surgical Procedures, Operative - adverse effects | beta-Alanine - adverse effects | Drug Administration Schedule | Risk Assessment | Administration, Oral | Hemorrhage - therapy | Risk Factors | Emergencies | Treatment Outcome | Anticoagulants - adverse effects | Anticoagulants - blood | Hemorrhage - diagnosis | Coagulants - therapeutic use | Blood Coagulation - drug effects | Hemostatic Techniques | Antithrombins - adverse effects | Antithrombins - blood | Blood Coagulation Tests | Hemorrhage - chemically induced | Coagulants - adverse effects
Journal Article
Nature Reviews Cardiology, ISSN 1759-5002, 05/2018, Volume 15, Issue 5, pp. 273 - 281
The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban,... 
ANDEXANET ALPHA | CARDIAC & CARDIOVASCULAR SYSTEMS | DABIGATRAN REVERSAL | HEALTHY-SUBJECTS | COAGULATION ASSESSMENT | PROTHROMBIN COMPLEX CONCENTRATE | LABORATORY MEASUREMENT | ACUTE INTRACEREBRAL HEMORRHAGE | NONVALVULAR ATRIAL-FIBRILLATION | FACTOR XA INHIBITOR | ACTIVATED FACTOR-VII | Perioperative Care | Recombinant Proteins - therapeutic use | Anticoagulants - administration & dosage | Postoperative Hemorrhage - prevention & control | Humans | Postoperative Hemorrhage - chemically induced | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Arginine - analogs & derivatives | Factor Xa - therapeutic use | Factor Xa - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Blood Loss, Surgical - prevention & control | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Assessment | Administration, Oral | Risk Factors | Treatment Outcome | Piperazines - therapeutic use | Anticoagulants - adverse effects | Piperazines - adverse effects | Coagulants - therapeutic use | Animals | Blood Coagulation - drug effects | Arginine - adverse effects | Antidotes - adverse effects | Hemorrhage - chemically induced | Arginine - therapeutic use | Coagulants - adverse effects | Antidotes - therapeutic use | Practice guidelines (Medicine) | Complications and side effects | Anticoagulants (Medicine) | Dosage and administration | Research | Anticoagulants | Patients | Coagulation
Journal Article
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 01/2018, Volume 233, Issue 1, pp. 153 - 161
Peroxisome proliferator‐activated receptors (PPARs) are ligand‐activated transcription factors involved in several physiological processes. PPAR ligands have a... 
cardiovascular disease | lipids | metabolism | peroxisome proliferator‐activated receptors | diabetes | therapy | peroxisome proliferator-activated receptors | INTIMA-MEDIA THICKNESS | METABOLIC SYNDROME | PHYSIOLOGY | RANDOMIZED CONTROLLED-TRIAL | SIMVASTATIN PLUS FENOFIBRATE | CELL BIOLOGY | INSULIN-RESISTANCE | ORAL FAT LOAD | PPAR-GAMMA AGONISTS | CORONARY-HEART-DISEASE | TYPE-2 DIABETES-MELLITUS | ALPHA/DELTA AGONIST GFT505 | Hypoglycemic Agents - therapeutic use | Peroxisome Proliferator-Activated Receptors - agonists | Hypolipidemic Agents - adverse effects | Humans | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Animals | Anti-Inflammatory Agents - adverse effects | Signal Transduction - drug effects | Peroxisome Proliferator-Activated Receptors - metabolism | Anti-Inflammatory Agents - therapeutic use | Ligands | Hypolipidemic Agents - therapeutic use | Hypoglycemic Agents - adverse effects | Physiological aspects | Carbohydrate metabolism | Drugs | Physiological effects | Transcription factors | Dyslipidemia | Differentiation (biology) | Lipids | Training | Proteins | Receptors | Atherosclerosis | Tumorigenesis | Blood pressure | Lipid metabolism | Heart diseases | Sensitizing | Carbohydrates | Pioglitazone | Diabetes mellitus | Coagulants | Metabolism | Insulin | Arteriosclerosis | Fibrosis | Rosiglitazone | Clinical medicine | Peroxisome proliferator-activated receptors | Index Medicus
Journal Article
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 06/2015, Volume 13, Issue 6, pp. 967 - 977
Prophylactic factor replacement, which prevents hemarthroses and thereby reduces the musculoskeletal disease burden in children with hemophilia A, requires... 
coagulation factor | hemophilia A | recombinant fusion proteins | VIII | children | prophylaxis | Children | Coagulation factor VIII | Recombinant fusion proteins | Hemophilia A | Prophylaxis | Recombinant Fusion Proteins - immunology | Factor VIII - immunology | Hemarthrosis - diagnosis | Age Factors | Recombinant Fusion Proteins - adverse effects | Factor VIII - pharmacokinetics | Humans | Child, Preschool | Half-Life | Male | Immunoglobulin Fc Fragments - administration & dosage | North America | Hemarthrosis - blood | Immunoglobulin Fc Fragments - immunology | China | Coagulants - administration & dosage | Factor VIII - adverse effects | Female | Hemophilia A - prevention & control | Coagulants - pharmacokinetics | Hemophilia A - diagnosis | Child | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Severity of Illness Index | Drug Administration Schedule | Europe | Risk Factors | Treatment Outcome | Hemophilia A - blood | Hemarthrosis - drug therapy | Recombinant Fusion Proteins - pharmacokinetics | Factor VIII - administration & dosage | South Africa | Infusions, Intravenous | Australia | Coagulants - adverse effects | Coagulants - immunology | Hemarthrosis - prevention & control | Hemophilia A - drug therapy | Antibodies, Neutralizing - blood | Prevention | Proteins | Care and treatment | Blood coagulation factor VIII | Hemophilia | Index Medicus
Journal Article
Journal Article